Who Should Receive Immunotherapy for Advanced Gastroesophageal Cancer?
Author:
Publisher
Springer Science and Business Media LLC
Link
https://link.springer.com/content/pdf/10.1007/s11864-024-01189-1.pdf
Reference29 articles.
1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistiCS 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209–49.
2. Paydary K, Reizine N, Catenacci DVT. Immune-checkpoint inhibition in the treatment of gastro-esophageal cancer: a closer look at the emerging evidence. Cancers. 2021;13:5929.
3. Shiravand Y, Khodadadi F, Kashani SMA, Hosseini-Fard SR, Hosseini S, Sadeghirad H, et al. Immune checkpoint inhibitors in cancer therapy. Curr Oncol. 2022;29:3044–60.
4. • Zhou KI, Peterson B, Serritella A, Thomas J, Reizine N, Moya S, et al. Spatial and temporal heterogeneity of PD-L1 expression and tumor mutational burden in gastroesophageal adenocarcinoma at baseline diagnosis and after chemotherapy. Clin Cancer Res. 2020;26:6453–63. This reference is of importance because it discusses the intricate challenges and complexities encountered with PD-L1 immunohistochemistry assays, notably issues related to reproducibility, heterogeneity, and subjectivity, in the context of gastroesophageal cancer. By highlighting the consistent correlation between higher CPS scores and an increased likelihood of clinical benefit, while also navigating through the debate on the efficacy of PD-L1 as a standalone biomarker, the reference provides a critical foundation. It thereby aids in exploring and validating alternative or complementary biomarkers, ensuring informed and nuanced discussions and investigations in future immunotherapy response studies across gastroesophageal cancer trials.
5. • Park R, Da Silva LL, Saeed A. Immunotherapy predictive molecular markers in advanced gastroesophageal cancer: MSI and beyond. Cancers. 2021;13:1715. This reference is of importance because it sheds light on the potential and early promise of various markers while emphasizing the necessity for their further prospective evaluations in the context of gastroesophageal cancer.
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3